APA (7th ed.) Citation

Brunelli, M., Buti, S., Rebuzzi, S., Milella, M., Vellone, V., Bersanelli, M., . . . Fornarini, G. (2020). 802TiP Immune tumor microenvironment (TME) in correlation with peripheral blood immune biomarkers as prognostic factor in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: The multicentric retrospective Meet-URO 18 study. Annals of Oncology, 31, S607. https://doi.org/10.1016/j.annonc.2020.08.2073

Chicago Style (17th ed.) Citation

Brunelli, M., et al. "802TiP Immune Tumor Microenvironment (TME) in Correlation with Peripheral Blood Immune Biomarkers as Prognostic Factor in Metastatic Renal Cell Carcinoma (mRCC) Patients Treated with Nivolumab: The Multicentric Retrospective Meet-URO 18 Study." Annals of Oncology 31 (2020): S607. https://doi.org/10.1016/j.annonc.2020.08.2073.

MLA (9th ed.) Citation

Brunelli, M., et al. "802TiP Immune Tumor Microenvironment (TME) in Correlation with Peripheral Blood Immune Biomarkers as Prognostic Factor in Metastatic Renal Cell Carcinoma (mRCC) Patients Treated with Nivolumab: The Multicentric Retrospective Meet-URO 18 Study." Annals of Oncology, vol. 31, 2020, p. S607, https://doi.org/10.1016/j.annonc.2020.08.2073.